Lung Adenocarcinoma Brain Metastases Survival Analysis with 172 Patients

A 36.5-month median follow-up study of 172 treatment-naïve, driver-negative lung adenocarcinoma patients with synchronous brain metastases, comparing immunochemotherapy alone versus combined with brain radiotherapy. The dataset includes primary and secondary clinical endpoints such as overall survival (OS) and intracranial progression-free survival (iPFS).

Use Cases

• Analyze overall survival (OS) differences between the Combination and Systemic therapy groups using hazard ratios and median OS values.
• Compare intracranial progression-free survival (iPFS) and objective response rates (iORR) across patient cohorts to assess radiotherapy impact.
• Perform multivariate analysis to verify brain radiotherapy as an independent favorable factor for OS and iPFS.
• Evaluate safety profiles and severe immune-related toxicities between the two treatment strategies.

Strengths

• 172-patient cohort provides a defined sample for comparative survival analysis.
• Median follow-up of 36.5 months offers substantial longitudinal observation.
• Study reports multiple validated endpoints including OS, iPFS, PFS, iORR, and eORR.

Limitations

• Small cohort size of 172 patients limits statistical power for subgroup analyses.
• Retrospective study design introduces potential selection bias and confounding factors.
• Data is contained in a DOCX document, requiring manual extraction for computational analysis.

Provenance

Source

figshare, author Rui Wang.

Collection Method

Retrospective cohort study.

Time Range

Study period not specified; median follow-up was 36.5 months.

Freshness

Last updated March 2026.

Geography

null